A multicentre, open, prospective study analysing efficacy of NETUPITANT/PALONOSETRON and Dexamethasone to Prevent Chemotherapy-Induced Nausea and Vomiting (CINV) in Hodgkin's Lymphoma
Latest Information Update: 12 Jan 2021
At a glance
- Drugs Dexamethasone (Primary) ; Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 12 Jan 2021 New trial record
- 08 Dec 2020 Primary endpoint has been met. (complete response)
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology